15289-s-bos

7 111 | Latest developments in the treatment of lipoprotein (a) Compound Effect Lp(a) * Effect other lipoproteints Dicussed study on effect Lp(a) Assay used in discussed study Effect cardiovascular events Conclusion Mipomersen Decrease 21-28% Decrease TG 25-33% Decrease VLDL-C 33-37% Decrease LDL-C 28- 37% Stein et al. [30] Thomas et al. [31] Northwest Lipid Research Clinic Protocol Unknown Decreases Lp(a) Improves lipoprotein profile Unknown effect on cardiovas- cular events Registered for Homozygous FH only Lomitapide + fat restric- ted diet No effect Decrease TG 31% Decrease VLDL 31% Decrease LDL-C 38% Cuchel et al. [32] Unknown Unknown No effect on Lp(a) Unknown effect on cardiovas- cular events Registered for Homozygous FH only CETP-inhibi- tors Decrease 50% Decrease TG 6% Decrease LDL-C 32% Increase HDL-C 160% Teramoto et al. [33] Unknown Unknown Decreases Lp(a) Improves Lipoprotein profile Unknown effect on cardiovas- cular events PCSK-9 monoclonal antibodies Decrease 30-40% Decrease LDL-C 55- 65% Davidson et al. [36] Desai et al. [37] Raal et al. [38] Blom at al. [39] AMGEN: Denka Seiken REG/SAN: Randox. Unknown Decreases Lp(a) Improves lipoprotein profile Unknown effect on cardiovas- cular events Table 7.1 | Continued